Sumitomo Pharma revenue and financials
¥1,621.00Change from previous close: +2.66%Absolute change: +¥42.00
In the fiscal year ended March 2026, Sumitomo Pharma reported revenue of ¥453.29B (+13.66% year over year). Net income was ¥106.87B, a net margin of 23.6%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +13.66%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +352.17%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 23.6%
- FY to Mar 2025: 5.9%
Financial data
Amounts in millions of JPY; per-share values in JPY; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 |
|---|---|---|---|---|---|
| Total assets | 804,571 | 742,604 | 907,506 | 1,134,742 | — |
| Current assets | 279,252 | 253,168 | 269,569 | 381,860 | — |
| Cash and equivalents | 44,310 | 23,116 | 29,047 | 143,478 | — |
| Short-term investments | 5,327 | 16,840 | 7,085 | 20,174 | — |
| Inventory | 85,414 | 94,222 | 115,350 | 94,405 | — |
| Net property, plant and equipment | 44,231 | 46,648 | 57,895 | 58,909 | — |
| Goodwill | 211,098 | 197,406 | 199,783 | 209,415 | — |
| Other intangible assets | 160,474 | 172,509 | 195,652 | 329,314 | — |
| Long-term investments | 36,400 | 5,588 | 360 | — | — |
| Current liabilities | 271,500 | 240,603 | 515,474 | 372,694 | — |
| Accounts payable | 56,698 | 38,544 | 67,720 | 52,141 | — |
| Long-term debt | 179,056 | 258,982 | 133,367 | 244,128 | — |
| Total debt | 217,186 | 305,422 | 418,884 | 334,716 | — |
| Total liabilities | 512,104 | 573,125 | 751,370 | 727,960 | — |
| Total equity (incl. minority) | 292,467 | 169,479 | 156,136 | 406,782 | — |
| Retained earnings | 158,981 | 46,784 | -22,665 | 280,999 | — |
| Minority interest | — | 0.0 | 73.0 | 33.0 | 65,681 |